Revolution Medicines, Inc. (RVMD) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Redwood City, CA, United States. The current CEO is Mark A. Goldsmith.
RVMD has IPO date of 2020-02-13, 616 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $29.13B.
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel therapies targeting RAS-addicted cancers. The company's pipeline includes several investigational programs, such as RMC-4630, an SHP2 inhibitor currently in Phase 1/2 trials for solid tumors including gynecologic and colorectal cancers, as well as RMC-5845, RMC-5552, RMC-6291, and RMC-6236, which target various components of RAS signaling pathways. Revolution Medicines has established a collaboration with Sanofi for the research and development of SHP2 inhibitors. Founded in 2014 and based in Redwood City, California, the company is advancing precision medicine approaches to address cancers driven by RAS mutations.
